Study of the efficacy and safety of maintenance Irinotecan in patients with extended small cell lung cancer after 4 courses of Cisplatin plus Irinotecan chemotherapy.
Not Applicable
- Conditions
- extended small cell lung cancer
- Registration Number
- JPRN-UMIN000008821
- Lead Sponsor
- Division of Thoracic Oncology, National Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
1)Active multiple malignacy 2)Grave complications 3)Bacterial infectious or fungus infection 4)Diarrhea 5)Paresis of intestine or ileus 6)Interstitial pneumonia or pulmonary fibrosis on chest CT 7)Dose of Irinotecan in prior chemotherapy is >60 mg/m2 at fourth course 8)Uncontrolled diabetes 9)Grave heart disease 10)Psychological disease decided not to be registered to this study 11)Pregnant or lactating women 12)Gastroduodenal ulcer 13)Grave complications 14)Doctor's decision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method